Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio su REGN5668 somministrato in combinazione con cemiplimab o REGN4018 in donne adulte con carcinoma ovarico ricorrente

20 settembre 2026 aggiornato da: Regeneron Pharmaceuticals

Studio di fase 1/2 su REGN5668 (MUC16xCD28, un bispecifico costimolatorio) somministrato in combinazione con Cemiplimab o REGN4018 (MUC16xCD3)

This study is researching an investigational drug called REGN5668 :

  • alone or,
  • combined with cemiplimab (also known as REGN2810) or,
  • combined with both cemiplimab and fianlimab (also known as REGN3767), or
  • combined with ubamatamab (also known as REGN4018), with or without sarilumab.

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
  • To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

612

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, Belgio, 3000
        • Reclutamento
        • Universitair Ziekenhuis Leuven
      • São Paulo, Brasile, 01509-010
        • Reclutamento
        • AC Camargo Cancer Center, Fundacao Antonio Prudente
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasile, 90619-900
        • Reclutamento
        • Centro de Pesquisa em Oncologia PUCRS
    • São Paulo
      • Barretos, São Paulo, Brasile, 14784-400
        • Reclutamento
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Sorocaba, São Paulo, Brasile, 18065-100
        • Reclutamento
        • Unimed Sorocaba
      • Villejuif, Francia, 94805
        • Reclutamento
        • Institut Gustave Roussy
    • Auvergne-Rhône
      • Pierre-Bénite, Auvergne-Rhône, Francia, 69310
        • Reclutamento
        • Hopital Lyon Sud
    • Bourgogne-Franche-Comté
      • Dijon, Bourgogne-Franche-Comté, Francia, 21000
        • Reclutamento
        • Centre Georges Francois Leclerc
    • New Aquitaine
      • Bordeaux, New Aquitaine, Francia, 33076
        • Reclutamento
        • Institut Bergonie
    • Normandy
      • Caen, Normandy, Francia, 14076
        • Reclutamento
        • Centre Francois Baclesse (CFB)
      • Girona, Spagna, 17007
        • Reclutamento
        • Institut Catala dOncologia Girona
      • Madrid, Spagna, 28040
        • Reclutamento
        • Hospital Universitario Fundacion Jimenez
      • Madrid, Spagna, 28040
        • Reclutamento
        • Ciudad Universitaria
      • Madrid, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
    • A Coruna
      • Santiago de Compostela, A Coruna, Spagna, 15706
        • Reclutamento
        • Hospital Clinico Universitario Santiago de Compostela
    • California
      • Duarte, California, Stati Uniti, 91010
        • Reclutamento
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, Stati Uniti, 92618
        • Reclutamento
        • The City of Hope Orange County Lennar Foundation Cancer Center
      • Orange, California, Stati Uniti, 92868
        • Reclutamento
        • Chao Family Comprehensive Cancer Center
    • Florida
      • Tampa, Florida, Stati Uniti, 33612
        • Completato
        • H. Lee Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Stati Uniti, 60611
        • Reclutamento
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      • Chicago, Illinois, Stati Uniti, 60637
        • Reclutamento
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02114
        • Reclutamento
        • Massachusetts General Hospital
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Dana Farber Cancer Institute Brookline Avenue
    • Michigan
      • Detroit, Michigan, Stati Uniti, 48201
        • Reclutamento
        • Karmanos Cancer Institute
    • New York
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43210
        • Reclutamento
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stati Uniti, 19104
        • Reclutamento
        • Perelman School of Medicine at the University of Pennsylvania
    • Washington
      • Seattle, Washington, Stati Uniti, 98109
        • Reclutamento
        • Seattle Cancer Care Alliance at South Lake Union - G3630

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Key Inclusion Criteria:

  1. Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
  2. Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
  3. Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
  4. Has adequate organ and bone marrow function as defined in the protocol
  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Has a life expectancy of at least 3 months
  7. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol

Key Exclusion Criteria:

  1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
  2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
  3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy
  4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
  5. Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
  6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
  7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
  8. Has history of clinically significant cardiovascular disease as defined in the protocol
  9. Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Module 1

REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab

Administer per the protocol

Altri nomi:
  • ubletamig

Administer per the protocol

Altri nomi:
  • REGN2810
  • Libtayo®

Administer per the protocol

Sperimentale: Module 2

REGN5668 and ubamatamab

Administer per the protocol

Altri nomi:
  • ubletamig

Administer per the protocol

Altri nomi:
  • REGN4018

Administer per the protocol

Altri nomi:
  • Kevzara®

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidence of Dose Limiting Toxicities (DLT)
Lasso di tempo: 42 days

Dose escalation phase, Module 1

42 days
Incidence of DLTs
Lasso di tempo: 21 days post combination administration

Dose escalation phase, Module 2

21 days post combination administration
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Lasso di tempo: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of Serious Adverse Events (SAEs)
Lasso di tempo: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of deaths
Lasso di tempo: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Lasso di tempo: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Lasso di tempo: Through study completion, up to 5 years

Primary: Dose escalation phase

Through study completion, up to 5 years
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Lasso di tempo: Through study completion, up to 5 years

Primary: Dose expansion phase

Through study completion, up to 5 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
ORR based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years

Dose escalation phase

Through study completion, up to 5 years
Best Overall Response (BOR) based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Duration Of Response (DOR) based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Disease Control Rate (DCR) based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Progression-Free Survival (PFS) based on RECIST 1.1
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against REGN5668
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against ubamatamab
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against cemiplimab
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against fianlimab
Lasso di tempo: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Clinical Trial Management, Regeneron Pharmaceuticals

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

8 dicembre 2020

Completamento primario (Stimato)

8 novembre 2028

Completamento dello studio (Stimato)

8 novembre 2028

Date di iscrizione allo studio

Primo inviato

9 ottobre 2020

Primo inviato che soddisfa i criteri di controllo qualità

9 ottobre 2020

Primo Inserito (Effettivo)

19 ottobre 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

24 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • R5668-ONC-1938
  • 2022-501904-83-00 (Ctis)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Periodo di condivisione IPD

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

Criteri di accesso alla condivisione IPD

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • CODICE_ANALITICO
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .